John Knight is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 17 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
971 Lakeland Dr Ste 450
Jackson, MS 392164615
Telephone
601-948-5158Provider last certified this registry record 11 May 2023.
Clinical trials
- Oxalate Formation From Ascorbic Acid
Sponsor: University of Alabama at Birmingham
- Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion
Sponsor: University of Alabama at Birmingham
- Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care
Sponsor: Boston Children's Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
51 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Corcept TherapeuticsProgram year202513 payments
- Novartis Pharmaceuticals CorporationProgram year202513 payments
- Amgen Inc.Program year202514 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
49.1%Insulin Analog9.9%Lantus Solostar19%Tresiba Flextouch U-10019%Tresiba Flextouch U-20014%Novolog Flexpen13%Fiasp Flextouch11%Basaglar Kwikpen U-1006%Soliqua 100-336%Humalog Kwikpen U-1005%Novolog5%Insulin Lispro3%Part D<11 patientsGLP-1 receptor agonist9.7%Ozempic57%Mounjaro23%Trulicity14%Rybelsus6%Part D<11 patients+ 9 more classes in this area
Cardiovascular
27.4%Statin9.8%Atorvastatin Calcium39%Rosuvastatin Calcium38%Pravastatin Sodium18%Simvastatin6%Part D<11 patientsAngiotensin receptor blocker (ARB)3.4%Losartan Potassium65%Losartan-Hydrochlorothiazide24%Valsartan11%Part D<11 patients+ 11 more classes in this area
Hormonal (systemic)
16.2%l-Thyroxine13.9%Levothyroxine Sodium77%Synthroid23%Part D≥109 patientsThyroid Hormone Synthesis Inhibitor1.6%Methimazole100%Part D≥18 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”